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Abstract
Background: World Health Organization (WHO) adolescent HIV-testing and treatment guidelines recommend
community-based interventions to support antiretroviral therapy (ART) adherence and retention in care, while
acknowledging that the evidence to support this recommendation is weak. This cluster randomized controlled trial
aims to evaluate the effectiveness and cost-effectiveness of a psychosocial, community-based intervention on HIV-
related and psychosocial outcomes.
Methods/design: We are conducting the trial in two districts. Sixteen clinics were randomized to either enhanced
ART-adherence support or standard of care. Eligible individuals (HIV-positive adolescents aged 13–19 years and
eligible for ART) in both arms receive ART and adherence support provided by adult counselors and nursing staff.
Adolescents in the intervention arm additionally attend a monthly support group, are allocated to a designated
community adolescent treatment supporter, and followed up through a short message service (SMS) and calls plus
home visits. The type and frequency of contact is determined by whether the adolescent is “stable” or in need of
enhanced support. Stable adolescents receive a monthly home visit plus a weekly, individualized SMS. An additional
home visit is conducted if participants miss a scheduled clinic appointment or support-group meeting. Participants
in need of further, enhanced, support receive bi-weekly home visits, weekly phone calls and daily SMS. Caregivers
of adolescents in the intervention arm attend a caregiver support group. Trial outcomes are assessed through a
clinical, behavioral and psychological assessment conducted at baseline and after 48 and 96 weeks. The primary
outcome is the proportion who have died or have virological failure (viral load ≥1000 copies/ml) at 96 weeks.
Secondary outcomes include virological failure at 48 weeks, retention in care (proportion of missed visits) and
psychosocial outcomes at both time points. Statistical analyses will be conducted and reported in line with
CONSORT guidelines for cluster randomized trials, including a flowchart.
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Discussion: This study provides a unique opportunity to generate evidence of the impact of the on-going Zvandiri
program, for adolescents living with HIV, on virological failure and psychosocial outcomes as delivered in a real-
world setting. If found to reduce rates of treatment failure, this would strengthen support for further scale-up across
Zimbabwe and likely the region more widely.
Trial registration: Pan African Clinical Trial Registry database, registration number PACTR201609001767322 (the
Zvandiri trial). Retrospectively registered on 5 September 2016.
Keywords: HIV, Antiretroviral therapy, Adolescents, Adherence, Zimbabwe, Psychosocial, Community-based
Background
In sub-Saharan Africa, the number of HIV-related deaths
among adolescents (aged 10–19 years) tripled between
2000 and 2014 despite decreasing among all other age
groups. HIV is now the leading cause of death among
this age group [1, 2]. The increase in adolescent HIV-
related deaths has been attributed to poor prioritization
of adolescents in national HIV plans, inadequate
provision of accessible and acceptable HIV-testing,
counseling and treatment services for this age group,
plus a lack of tailored support for adolescents to remain
in care and adhere to taking antiretroviral therapy
(ART) [3–5]. Adolescents in sub-Saharan Africa have
poorer ART adherence than adults [6] and are at high
risk of loss to follow-up from treatment and care [7].
This supports findings among adolescents with other
chronic childhood illnesses (e.g., diabetes, asthma) when
medication adherence frequently becomes worse as the
child becomes more independent from parental control
as they enter adolescence [8].
In 2013, the World Health Organization (WHO) re-
leased the first consolidated ART prevention and treat-
ment guidelines which recommended innovative models
of ART delivery (decentralization, integration and task-
shifting) [9]. In response, Zimbabwe revised its national
ART guidance, released in December 2013, to simplify
recommended treatment regimens for children and ado-
lescents, hence facilitating the decentralization of
pediatric HIV care to primary healthcare facilities [10].
Decentralizing pediatric HIV care has resulted in im-
proved access and coverage, but little is known about
the capacity of primary care facilities to provide effective
adherence support as well as support for the broader
psychosocial issues that many of these children and ado-
lescents face [4].
A key tenet of both the WHO and Zimbabwe’s treat-
ment guidelines is that expanded access to ART needs
to be accompanied by interventions to maximize reten-
tion in care and medication adherence. Poor retention
and adherence to ART leads to treatment resistance and
ultimately, to treatment failure [5, 11, 12]. International
guidelines recommend at least 95% adherence to ART to
minimize the risk of virological failure [13–15]. A sys-
tematic review of 17 studies relating to ART programs
in children and adolescents from low- and middle-
income countries (LMIC) found that non-adherence was
associated with a child’s socioeconomic environment,
stigma, caregiver characteristics, dynamics of child-
caregiver interactions, disclosure of HIV status, regimen
complexity, side effects, and cost of medication [16].
The 2013 and 2015 WHO adolescent HIV-testing and
treatment guidelines recommend community-based in-
terventions to support ART adherence and retention in
care, while acknowledging that the evidence to support
this recommendation is weak [4, 17]. Evidence-based
strategies to provide support to the growing number of
adolescents receiving ART from LMIC are urgently re-
quired. Preliminary evidence suggests that the Zvandiri
(“As I am”) program (http://www.africaid-zvandiri.org/)
has the potential to make a significant impact on the
lives of adolescents living with HIV [18].
The Zvandiri program is a model of differentiated clin-
ical service delivery for HIV-positive children and ado-
lescents in Zimbabwe, has been cited as a “best practice”
intervention by the WHO [4], USAID, Southern African
Development Community [19], and has been recom-
mended for adaptation and regional scale-up [19]. The
program uses trained and mentored community adoles-
cent treatment supporters (CATS) to deliver structured
support groups and tailored community-based adher-
ence support coupled with counseling for the broader
psychosocial issues that these young people are facing
(including coming to terms with their emerging sexuality
in the context of a life-threatening, sexually transmis-
sible infection). The CATS are aged 18–23 years, living
with HIV, have been identified by the healthcare facility
as committed, competent and motivated to support their
peers as well as adherent to ART, having completed sec-
ondary schooling and having consent from their care-
givers to enroll as CATS. The Zvandiri program also
includes an intervention for caregivers which focuses on
enhancing their knowledge, skills and confidence of HIV
and treatment literacy as well as communication and
parenting through a participatory training program.
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In this paper we describe the protocol for a cluster
randomized controlled trial (cRCT) to evaluate the ef-
fectiveness and cost-effectiveness of the Zvandiri pro-
gram on HIV-related and psychosocial outcomes.
Methods/design
Objectives
The trial will provide evidence on whether enhancing
community-based support for adolescents on ART
through the Zvandiri program will, compared with
standard care:
1. Reduce the proportion of adolescents with ART
treatment failure (lack of viral suppression)
2. Improve retention in care
3. Reduce the severity of anxiety and depression
4. Reduce the proportion of adolescents reporting non-
disclosure
5. Be cost-effective
Hypotheses
The primary hypothesis is that the Zvandiri program will
be more effective than standard care in reducing the
proportion of adolescents who have died or who are fail-
ing treatment at 96 weeks (defined as a viral load ≥ 1000
copies/ml).
The secondary hypotheses are that the Zvandiri pro-
gram (1) improves virological failure at 48 weeks, (2) im-
proves retention in care, (3) reduces psychological
distress, (4) increases HIV status disclosure to sexual
partners and (5) decreases perceived stigma.
Trial setting
The trial is being conducted in two districts (Bindura
and Shamva) in Mashonaland Central Province. The dis-
tricts were selected in consultation with the Ministry of
Health and Child Care (MoHCC). At the time of selec-
tion, it was estimated that 24,871 adolescents were living
with HIV in the province and that ART coverage among
children and adolescents was the lowest in Zimbabwe
(estimated to be 29%). Additionally, although the Zvan-
diri program was being scaled-up, it had not yet been
initiated in these two districts. Altogether, there are 33
healthcare facilities in the two districts. Of these, 16 with
at least 20 adolescents on ART (excluding private clinics
and those not yet offering pediatric HIV treatment and
care services) were selected to participate.
Trial design
The trial is a cluster randomized controlled trial (cRCT).
The clinic is the unit of randomization. Sixteen clinics
were randomized to either enhanced ART-adherence
support through the Zvandiri program or standard of
HIV care in a 1:1 allocation (Fig. 1). Adolescents aged
13–19 years were recruited. Trial outcomes are assessed
through a clinical, behavioral and psychological assess-
ment conducted at baseline and after 48 and 96 weeks.
Eligibility criteria
1. Inclusion criteria: HIV-positive adolescents, aged
13–19 years, eligible for ART (i.e., either starting or
already on ART) and able to provide informed
assent and their caregiver is able to provide
Fig. 1 Trial overview
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informed consent (those aged 18 and 19 years do
not need caregiver consent)
2. Exclusion criteria: too physically or psychologically
unwell or unable to give informed consent
Interventions
Control arm
All eligible adolescents attending clinics allocated to the
standard-care arm receive ART and adherence support
as set out in the prevailing MoHCC guidelines [20]. As
per MoHCC guidelines, adherence support is provided
by adult counselors and nursing staff. After ART initi-
ation, adolescents are seen monthly, with cluster of dif-
ferentiation 4 (CD4) monitoring at 6-monthly intervals.
Prescription refills, pill counts and participant interviews
are used to measure adherence. Although routine viral-
load testing was adopted by MoHCC in 2010 and scale-
up began in 2012 [21], the MoHCC is currently only
able to provide targeted rather than universal viral-load
testing.
Intervention arm
All eligible adolescents attending intervention clinics will
receive MoHCC standard care. In addition, one to three
(ideally at least one man, one woman) trained and sup-
ported CATS are at each clinic to provide adherence
counseling and support to adolescents at their clinic
visits as well as on-going individualized community-
based support. Each CATS supports 6–10 adolescents in
their geographical location irrespective of level of Zvan-
diri support. CATS were recruited from the clinic in
partnership with the clinic staff, or from the local sup-
port group if a group was already in place.
The CATS receive 2 weeks of MoHCC-endorsed train-
ing to equip them with counseling skills and skills in
community outreach plus knowledge specific to adoles-
cent HIV (ART and adherence, disclosure, sexual and re-
productive health, psychosocial support and mental
health). The training combines both theoretical and
practical components, including the “shadowing” of
existing CATS in Harare to acquire practical experience
of providing adherence support. Training includes learn-
ing how to identify “red flags” for ill-health, adherence
challenges, psychosocial distress and common mental
disorders (CMDs), plus basic skills in problem solving
and cognitive behavioral therapy (CBT). Training is par-
ticipatory and uses case studies. All CATS attend a
weekly supervision meeting at the clinic with a desig-
nated nurse and provide each other with peer-to-peer
support (through a WhatsApp group and via Skype from
Harare) with oversight from a professional counselor.
Trial participants are allocated to a designated CATS ac-
cording to their residential area and followed up through
the short message service (SMS), phone calls and home
visits. The type and frequency of contact is determined
following assessment of their individual situation (i.e.,
whether they are considered “stable” or in need of en-
hanced support):
1. “Stable” adolescents are those: (a) with a viral load <
1000 copies/ml and/or most recent (and within the
last 6 months) CD4 count ≥ 200 cells/ml and (b)
attending all scheduled clinic visits in the last
3 months assessed using the patient-held record.
Stable adolescents receive a home visit once a
month, plus a weekly, individualized SMS. The SMS
is written and sent by the CATS and focuses on (i)
motivational reminders around adherence, (ii) clinic
and support group attendance and (iii) encourage-
ment to contact the CATS in the event of any prob-
lems. An additional home visit is conducted if an
adolescent misses a scheduled clinic appointment or
support-group meeting
2. Adolescents in need of enhanced support are those:
(a) with a viral load ≥ 1000 copies/ml and/or CD4
count < 200 cells/ml, (b) at risk of other CMDs/with
a major depressive disorder (assessment methods
described below), (c) failing to attend one or more
scheduled clinic visits in the last 3 months, (d)
commencing ART in the past 3 months, (e) who are
pregnant and (f ) with other psychosocial challenges
or protection issues. Adolescents in need of
enhanced support receive bi-weekly home visits, plus
weekly phone calls and daily SMS. During the home
visit, the CATS conduct an adherence assessment
and provide adherence counseling as appropriate. A
community health nurse accompanies the CATS
where possible. If adolescents require more than one
home visit every 2 weeks (for child protection cases,
depression, ill-health), these are conducted by CATS
with the caregiver present
Adolescents are allocated to the appropriate interven-
tion level at enrollment, and re-assessed at 3-monthly
intervals by the CATS in conjunction with the clinic
nurses. Adolescents are moved between levels of inter-
vention support as indicated by clinic attendance and
other clinical factors as outlined in Table 1.
All participants at Zvandiri intervention sites are in-
vited to attend a monthly support group, facilitated by a
support-group leader (a volunteer nurse, teacher or so-
cial worker) in conjunction with the CATS, with super-
vision from the intervention coordinator. A standardized
curriculum is used, focusing on improving health and
treatment literacy, HIV disclosure, resilience and coping
strategies, sexual and reproductive health, social net-
works and awareness of, and linkages to, services as re-
quired. Adolescents are actively followed up by the
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CATS to maximize attendance at this support group.
Adolescents identified to be at risk of harm are immedi-
ately referred to the Zvandiri intervention coordinator
or clinic nurse for mental health services and/or man-
agement with the Department of Social Services.
Zvandiri intervention conceptual framework
The Zvandiri intervention is informed by the Unified
Theory of Behavior (UTB) [22, 23]. The UTB is a vali-
dated conceptual framework that has previously been
adapted to support adolescent behavior change within
the context of a family centered approach. The UTB
conceptualizes behavior in terms of two dimensions –
the immediate determinants of behavior, and of behav-
ioral intention. It states that adherence to ART (for ex-
ample) is more likely to occur if both (1) the
determinants of adhering to ART and (2) the intention
to adhere to ART are “aligned in favor of its enactment”
[22, 23]. The five immediate determinants of behavior
(i.e., ART adherence) are shown in Fig. 2, as are the im-
mediate determinants of behavioral intention (i.e.,
intention to adhere to ART). We used this framework,
combined with evidence from the academic literature
about the determinants of adolescent HIV adherence
and data from our formative work, to develop a modular
Zvandiri intervention ensuring that each component of
the framework is adequately addressed.
Caregivers of adolescents in the intervention arm are
invited to a 12-session caregiver support group, facili-
tated by the intervention coordinator and CATS over
12 months. Sessions are in Shona, the participants’ lan-
guage. The sessions focus on improving caregivers’
knowledge, skills and confidence of HIV and treatment
literacy, communication and parenting and available
support services. Two sessions are held jointly with
adolescents.
Table 1 Intervention components and levels of intervention support
Level of care Standard Zvandiri support Enhanced Zvandiri support
Eligibility criteria • A viral load < 1000 copies/ml in last 6 months
• CD4 count≥ 200 cells/ml in last 6 months
• Attending all scheduled clinic visits in last 3 months
• Psychologically stable
• Safe
• Commencing ART in past 3 months
• A viral load≥ 1000 copies/ml in the last 6 months
• CD4 count < 200 cells/ml last 6 months
• Pregnancy
• Failing to attend≥ 1 scheduled clinic visit(s) in last 3 months
• Psychological distress
• Abuse or neglect
Intervention • Monthly support group
• Monthly home visit
• Weekly SMS reminder
• Zvandiri Centre contact
• Caregiver workshop
• Monthly support group
• Bi-weekly home visits
• Daily SMS reminder
• Weekly phone calls
• Zvandiri Centre contact
• Caregiver workshop
• Referral and linkages
• Community outreach visits
ART antiretroviral therapy, SMS short message service
Fig. 2 Adolescent and family centered intervention for antiretroviral therapy (ART) adherence
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Definition of endline
The primary endpoint will be at 96 weeks post enroll-
ment. There will be an 8-week window period on either
side of this endpoint to allow flexibility in timing of visit
(i.e., 88–104 weeks).
Outcomes
The primary outcome is the proportion of participants
who have died or who have a viral load ≥ 1000 copies/ml
at 96 weeks, assessed on a dried blood-spot sample. Sec-
ondary outcomes are assessed at 48 and 96 weeks, and
are the proportion of participants:
1. Who are not retained in clinic services stratified
according to the WHO definition [24]. Full retention
is defined as attending > 80% of scheduled clinic
appointments; partial retention as attending 30–80%
of scheduled appointments and non-retention as <
30% attendance at scheduled appointments) [24].
Retention in services will be measured through at-
tendance at scheduled clinic visits (scheduled visit
defined as visit within ± 7 days of exact date)
2. Who discontinue ART defined as completely
stopping taking drugs for at least 3 months, as
documented in clinic records (3 months is the
minimum period associated with risk of progression
to new clinical AIDS events or death) [25, 26]
3. With depression, defined as scoring ≥ 10/27 on the
Patient Health Questionnaire (PHQ-9), a scale that
has been widely used in Africa [27, 28] and recently
validated for use in Zimbabwe [29]
4. With CMDs (depression and/or anxiety), defined as
scoring ≥ 8/14 on the Shona Symptom
Questionnaire (SSQ-14) which was developed and
validated in Zimbabwe using exemplary cross-
cultural methods [30]. This cut-point may be
amended prior to locking the analysis plan, based on
results of a separate validation study. Only two of its
items relate to somatic symptoms making it useful
in participants with physical disease. Severity of
CMDs will also be assessed using the SSQ-14 as a
continuous score
5. With poor quality of life, measured using a
previously-validated Shona version of the European
Quality of Life-5 Dimensions (EQ-5D) scale [31, 32]
Exploratory outcomes are assessed at 48 and 96 weeks,
and are the proportion of participants:
1. Self-reporting disclosure of HIV status to sexual
partners, assessed using a self-completed
questionnaire
2. Self-reporting perceived stigma measured using the
HIV/AIDS Stigma Instrument for people living with
AIDS (PLWA) (HASI-P) which has been validated in
Africa [33]
Sample size and potential power of the trial
The total sample size of 500 participants recruited from
16 clusters will provide 80% power to detect a difference
in detectable viral load of 35% among participants in the
standard-care arm versus 18% in the intervention arm
assuming 20% loss to follow-up and a coefficient of vari-
ation (k) between clusters of 0.25 [34]. For secondary
outcomes, the trial will have 90% power to detect, for
example, a difference in non-complete attendance of
26% in the standard-care arm versus 10% in the inter-
vention arm, and 80% power to detect a difference in
mean SSQ-14 [30] score of 7.4 in the control arm and
4.8 in the intervention arm (standard deviation (SD) =
3.74).
Study schedule
Figure 3 shows the study schedule which follows the
Standard Protocol Items: Recommendations for Inter-
vention Trials (SPIRIT) guidelines.
Randomization
Imbalance between arms was minimized by using re-
stricted randomization and matching of clusters on size
and number of people in HIV care. Sixteen clusters were
allocated 1:1 to either the immediate intervention or the
control arm. To maximize transparency and buy-in from
key stakeholders, a public randomization procedure was
undertaken on 5 July 2016 involving MoHCC, Commu-
nity Advisory Board members, and district-level govern-
ance and medical representatives.
Recruitment and enrollment procedures
From the 16 clusters, a list of eligible participants was
generated from the “pre-ART and ART Registers.” At
each cluster, selected village healthcare workers
(VHCWs) were asked to mobilize potential participants
after receiving training on trial objectives and proce-
dures, as well as confidentiality aspects. The research
team then held a trial-orientation meeting with the po-
tential participants plus their caregivers. After orienta-
tion and screening, participants and caregivers who
opted to take part in the trial and provided written con-
sent, plus assent to enroll, were booked for enrollment
procedures and baseline assessments. Recruitment and
enrollment in the intervention and control arms oc-
curred concurrently. At enrollment, participants were
informed that they would be allocated to either the
intervention or the control arm and told which one they
were allocated to afterwards. Recruitment started on 15
August 2016 and concluded on 31 March 2017.
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Quantitative data collection and management
At enrollment, participants complete a questionnaire using
an interviewer-administered, computer-assisted personal
interview (CAPI) with more sensitive questions likely subject
to socially desirability bias self-administered using an audio-
computer-assisted survey instrument (ACASI) [35, 36].
Questionnaire domains include: sociodemographic, socioeco-
nomic, medical history, including history of opportunistic in-
fections and hospitalization, HIV-testing history, ART
history, information on clinic attendances, information on
adherence (self-report), and psychological wellbeing. On
completion of the questionnaire, all participants are asked to
provide a finger-prick dried blood-spot sample for HIV viral-
load testing and undergo a clinical exam to assess WHO
stage. All viral-load test results will be returned to the clinic
within 3 months to guide clinical care (in both the interven-
tion and comparison arms). All trial participants are assessed
by the research team, in addition to their routine clinic visits,
after 48 and 96 weeks. At the follow-up visit, they will
complete a shortened version of the questionnaire, have a
finger-prick blood-spot sample taken for viral-load testing
and have a physical examination to allow clinical staging.
Quantitative data analysis
Data collected using ACASI and CAPI is downloaded
into a password-protected Access database. The data will
STUDY PERIOD
Allocation Enrolment
Post-allocation
Close-out
Interventions
Time point
0 Baseline
48 weeks 
follow-up
96 weeks 
follow-up
104 weeks
ALLOCATION: X
ENROLMENT: X
Eligibility screen X
Informed consent X X X
Survey procedures X X X
INTERVENTIONS:
Usual/standard care
Standard support & caregiver 
intervention
Enhanced support & caregiver 
intervention
ASSESSMENTS:
Primary outcome
Virological failure X X
Secondary outcomes
Retention in care X X
ART discontinuance X X
Depression X X
Common mental disorders X X
Quality of life X X
Exploratory outcomes
Self-reported disclosure of HIV 
status to sexual partners
X X
Self-reported stigma X X
Fig. 3 Schedule of enrollment, interventions and assessments following the Standard Protocol Items: Recommendations for Intervention Trials
(SPIRIT) guidelines
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be analyzed using Stata 14. Statistical analyses will be
conducted and reported in line with Consolidated Stan-
dards of Reporting Trials (CONSORT) guidelines [37]
including a flowchart. Baseline characteristics of enrolled
participants and the number continuing through the
trial, actively withdrawing, and passively lost to follow-
up will be shown by arm. The outcome measures will be
summarized at baseline, 48 and 96 weeks by intervention
arm, using proportions or means (SD) as appropriate.
Analyses will be intention-to-treat. Analyses will be
based on cluster-level summary measures, as individual-
level regression methods do not perform robustly when
there are relatively few clusters per arm, especially for
stratified cluster randomized trials [38]. For binary out-
comes, the impact will be estimated by the risk ratio
(RR) and risk difference (RD). The stratum-specific risk
ratios will be estimated as the ratio of the geometric
mean risks between arms for each of the two strata, and
the overall RR will be estimated as the weighted-average
of these stratum-specific risk ratios. An approximate
variance for the log of the mean risk in each arm will be
estimated from the residual mean square from a two-
way analysis of variance of community log-risk on strata
and study arm. A 95% confidence interval (CI) for the
RR will be estimated from this variance using a stratified
t test with 14 degrees of freedom. Similarly, a 95% CI for
the RD will be estimated from an analysis of variance of
the mean risk on strata and study arm. For continuous
outcomes, the measure of effect will be the mean differ-
ence between arms, analyzed in an analogous method
based on mean scores in each facility.
Secondary planned analyses will examine the impact
of the intervention separately by age group, gender, dur-
ation on treatment, with assessment of effect-
modification of the intervention effect by facility type
using a previously described method [39]. Pre-defined
sensitivity analyses will include adjustment for baseline
viral load and other variables imbalanced at baseline.
We will conduct sensitivity analyses to investigate the ef-
fect of missing data by using multiple imputation, ana-
lyzed using an individual-level Poisson regression model,
allowing for within-cluster correlation using generalized
estimating equations.
Qualitative data collection and management
Twenty-six participants (20 adolescents – 10 male; 10
female – from across the age range plus six carers) from
two intervention and two control communities will be
purposively selected for three serial, in-depth interviews
to understand the experiences of clinical care for chil-
dren and young people living with HIV. In addition, four
focus group discussions will be conducted with purpos-
ively selected participants and healthcare workers in
both the enhanced intervention- and standard-care
arms. All discussions will be audio-recorded; hand-
written notes will be taken down as back-up.
Qualitative data analysis
Audio-recordings will be transcribed, translated into
English, and coded by two independent coders in NVivo
(QSR International, Melbourne, VIC, Australia). Coders
will discuss discrepancies until consensus is reached.
Codes will be grouped and emerging themes will then
be identified. Analytic memos will be written for each
theme. During write-up, themes and sub-themes will be
illustrated with verbatim quotes.
Cost-effectiveness data collection and analysis
A cost-effectiveness analysis will be conducted using
standardized survey instruments and taking a provider
perspective, combining top-down and bottom-up cost-
ing. Study instruments will assemble data from program
records and facility staff on relative costs of personnel,
recurrent inputs and services, and capital costs (equip-
ment, vehicles and training) which will be discounted at
a 3% rate. Any donated inputs will be valued at their op-
portunity costs determined using local market prices.
Training and supervision will be valued according to op-
portunity cost of staff and CATS’ time dedicated to these
activities. Annual staff (providers and CATS) costs will
be derived from staff roster information from program
records and self-reports at the facility level; grades and
salaries for each type of staff; and time and motion ob-
servation (the “gold standard” in measuring staff alloca-
tion of time through direct observation).
All cost data will be collected prospectively by month
and analyzed in US dollars (the US$ has been the principal
currency in Zimbabwe since 2009). Any parameter uncer-
tainty, such as influence of staff time per client, will be
dealt with using univariate or multi-variate sensitivity ana-
lysis. As retention-in-care data (from trial) is only an inter-
mediary measure of impact, we will use appropriate
health-related quality of life (QALY) measures (e.g., EQ-
5D) to estimate QALYs gained for the purposes of cost-
effectiveness analysis. As intervention participants may
transition between different states (standard Zvandiri sup-
port or enhanced Zvandiri support) over the course of the
trial, a dynamic Markov model [40] will be used to track
costs of care and utility at each point in time. A more real-
istic incremental cost-effectiveness ratio (ICER) threshold,
WHO-CHOICE, which recommends a country gross do-
mestic product (GDP)-dependent approach, will be
adopted (http://www.who.int/choice).
Process evaluation data collection and management
The Intervention Monitoring and Process Evaluation
framework provides a structure for data collection to
capture progress along the hypothesized pathway from
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intervention activities to their intended outcomes. For
the process evaluation, we hypothesize that:
If there are adequate inputs (human resources,
partnerships and collaboration, established procedures
and protocols, effective trainings)
These will ensure a smooth process of implementation,
producing well-functioning outputs that will contribute
to the achievement of the intervention’s ultimate goals
(improved physical and psychological health) (see
Fig. 4)
Program records
Program data will be collected in intervention communi-
ties and regularly compiled to record uptake and attend-
ance at community intervention, visits by CATS and use
of clinical services.
Process evaluation data analysis
Service statistics and other quantitative data will be
double entered into a password-protected Access
database. Range and consistency checks will be per-
formed. Quantitative data will be analyzed using Stata
14. Process evaluation qualitative data will be ana-
lyzed in the same manner as other qualitative data
(already described).
Discussion
Effective strategies are urgently needed to reach the am-
bitious UNAIDS 90-90-90 target by 2020 (that 90% of all
people living with HIV will know their HIV status, 90%
of all people with diagnosed HIV infection are receiving
sustained ART, and 90% of all people receiving ART are
virologically suppressed) [41]. To achieve this, high-
Fig. 4 Intervention Monitoring and Process Evaluation framework
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quality programs will need to ensure high levels of re-
tention and adherence [11, 12].
Evidence-based strategies to support both adherence
and retention in care of young people are required. This
trial has the potential to generate robust evidence of the
impact of the Zvandiri program as delivered in a real-
world setting. If found to reduce rates of treatment fail-
ure, this would strengthen support for further scale-up
across Zimbabwe and likely the region more widely. In
addition, the results will directly influence policies and
standard of care for HIV-infected children in Zimbabwe,
regionally and internationally.
While the overall trial will answer the primary re-
search question, “Does the Zvandiri program improve the
physical and psychological health of adolescents living
with HIV resulting in improved clinical outcomes and
quality of life?” process evaluation and qualitative re-
search will provide some understanding of why and how
the intervention was able to lead to improved retention/
adherence along the HIV-care continuum (or suggest
reasons for lack of effect). Additionally, process evalu-
ation and qualitative research will suggest how the Zvan-
diri intervention could be modified for optimal impact
during any further scale-up.
Finally, most countries including Zimbabwe have re-
vised their HIV treatment guidelines in line with the
WHO 2015 revised treatment guidelines which recom-
mend a “test-and-start approach” for all those who are
HIV infected, not just pregnant women [17]. Since a sig-
nificant proportion of the likely beneficiaries of “test and
start” are likely to be young people, this trial will help
identify some of the challenges of this approach. Specif-
ically, the trial will provide needed information on the
capacity of primary care facilities to provide effective ad-
herence support as well as support for the broader psy-
chosocial issues that many of these young people face.
Trial status
At the time of initial manuscript submission recruitment
for this trial was on-going but not yet complete.
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